Active Pharmaceutical Ingredients

Acies Bio evolved from a biotech startup focused on optimizing production processes for actinomycetes. Development of various production technologies for secondary metabolites for pharma industry (e.g., antibiotics, immunosuppressants, and others) or impurity profile improvement is our expertise which we have been providing to pharmaceutical industry for two decades. Our deep understanding of metabolic pathways, genetic engineering, and fermentation processes with complex production microorganisms such as actinomycetes (Streptomyces, Saccharopolyspora, Amycolatopsis, etc.), myxobacteria, and others enables us to create innovative solutions.

To address industry needs, we offer:

• advanced microbial genetic engineering: We specialize in developing high-performing production strains optimized for biosynthesis of APIs and intermediates, ensuring high efficiency and yield improvement. Another important target is improvement of impurity profile which can significantly reduce DSP costs.
• mutagenesis and high-throughput screening approaches: Our tailored mutagenesis and screening approaches enable the rapid improvement of microbial strains, significantly enhancing productivity and metabolic efficiency.
• proprietary strain library: We have amassed a collection of microbial strains with modified metabolic fluxes, specifically designed for the production of different metabolites, e.g. nucleoside-based molecules and other valuable compounds.